Oligonucleotide-Based Therapy for Diagnosis and Treatment of Cancer

Karni Rotem, HUJI, School of Medicine - IMRIC, Biochemistry and Molecular Biology


Oncology, Cancer, Diagnostics

Development Stage

In vitro proof of concept and small animals

Patent Status

PCT application filed


Cancer testing is currently one of the most important growth opportunities diagnostics segment. The worldwide market for in vitro cancer diagnosis is estimated in few billions.


  • Detecting the ratios of specific splicing isoforms used to indicate presence of cancer and sensitivity/resistance to Ras-Raf-MEK and PI3K-mTOR inhibitors.
  • Successfully demonstrated ability to predict activation of specific signaling pathways and the sensitivity of cancer cells to specific drugs.
  • Changing the ratios of specific splicing events by antisense oligonucleotides inhibits cancer cell growth and sensitized them to anti-cancer drugs.
  • Alternative splicing changes are better markers for the activity of drugable signaling pathways.
  • Highly sensitive diagnostic tool
  • New treatment approach

Our Innovation

Novel approach to diagnosing cancer and a patient's sensitivity to specific drugs using the levels in the body of specific splicing isoforms and their ratios as markers; Specific alteration of splicing events by Antisense RNA oligos for the treatment of cancer

Key Features

  • Accurate prediction of tumor sensitivity/resistance to Ras-Raf-MEK and PI3K-mTOR inhibitors.
  • More Accurate diagnosis for efficient treatment  to prevent suffering of cancer patients
  • New Efficient treatment for resistant cancer cells.

Development Milestones

Seeking funding for ongoing research, further animal trials, and accumulation of patient data

The Opportunity

Applications in cancer personalized medicine and a new treatment for resistant cancer cells

Patent Status

Granted US 9,745,581

Contact for more information:

Mel Larrosa
VP Business Development Healthcare
Contact ME: